| Name | Title | Contact Details |
|---|
STARK Group is a leading provider of building materials and services for the construction industry in Europe. Founded in 1896 and headquartered in Frederiksberg, Denmark, the company operates over 1,100 branches and distribution centers across Europe, employing around 19,000 people. STARK Group specializes in the distribution and retail of building materials to professional builders and contractors. They offer product knowledge and advice to help customers select the right materials for their projects. The company also provides efficient logistics solutions to ensure timely delivery of products to construction sites. Their extensive product portfolio includes a wide range of heavy construction materials tailored to meet the diverse needs of the construction sector. STARK Group is committed to sustainability, investing in environmentally friendly facilities and aiming for low-emission classifications in their operations.
Chesapeake Bank is a community bank located in Kilmarnock, Virginia, serving the Northern Neck and Middle Peninsula regions. Established in April 1900 as Lancaster National Bank, it was founded to support local watermen, oystermen, and fishermen. Over the years, the bank has expanded its services to include farmers and various local businesses, adapting to the needs of the community. The bank offers a variety of banking services, including personal banking options like checking and savings accounts, personal loans, and credit cards. For businesses, Chesapeake Bank provides loans, lines of credit, and cash management services. Additionally, it offers investment services through Chesapeake Wealth Management. Known for its community-focused approach, Chesapeake Bank emphasizes treating customers like neighbors and actively engages in local initiatives.
Aegis Sortation is a technology and innovation leader specializing in the Freight and Parcel, Warehouse and Distribution, and E-Commerce industries. At Aegis we are innovating today to transform industries tomorrow! Innovation is the engine that drives our company forward and generates the creative forces behind everything we do and make. We are dedicated to providing exceptional service for our customers and exceeding industry standards for speed, durability, and safety. Our products are specifically designed to transform business; always, with no exceptions. This approach allows us to take advantage of both tried-and-true practices as well as applicable cutting-edge technologies. Aegis is determined to bring innovation, excellence and results to every project and partnership.
Archbold Furniture Company has been manufacturing solid wood furniture since 1900. For over 100 years we have worked to provide our customers with high-quality, solid wood products at an exceptional value. In 2010 we partnered with a premier Amish finisher. Since then, all of our finishes are applied by a select group of high-skilled Amish companies. The combination of efficient production methods and custom Amish finishes provides a unique value of high-quality solid wood furniture at affordable prices. Interested in joining our team? Contact HumanResources@archboldfurniture.com.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.